Pharmesis International Ltd. Returns to Profitability with New Herbal Segment
I'm PortAI, I can summarize articles.
Pharmesis International Ltd. has reported a return to profitability in FY2024, achieving a net profit of RMB8.3 million, with a 48.2% revenue increase to RMB67.6 million. This growth is attributed to the new Traditional Chinese Herbs (TCH) procurement segment. The company sources herbs from local farmers in Sichuan, maintaining a competitive edge. Additionally, Mr. Chew Heng Ching has been redesignated as non-Independent non-executive chairman. Pharmesis operates in the pharmaceutical industry, focusing on the procurement and distribution of TCH.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments